Mounjaro®
Starting from £179.99/mo
Start journey Learn moreMost people stay on Mounjaro for at least 12 to 18 months, and many continue beyond that. There is no single fixed treatment duration — how long you need to take it depends on how your weight responds, how well you tolerate it, and what your prescriber decides at each clinical review. Mounjaro (tirzepatide) is a prescription-only medicine, so these decisions are made with a qualified clinician, not independently. The short answer is that it is a medium-to-long-term treatment, not a short course.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
There is no hard expiry date written into Mounjaro's UK licence. The medicine is approved for weight management in adults with a BMI of 30 or above, or 27 or above alongside at least one weight-related health condition, and the licence does not cap the treatment at a specific number of months. What NICE does specify in its appraisal of tirzepatide (published in December 2024 and updated in September 2025) is a practical checkpoint: if someone has not lost at least 5% of their starting body weight after six months at the highest dose they can tolerate, the clinical justification for continuing needs to be reviewed. That is a decision point, not an automatic stop. You can read the NICE appraisal of tirzepatide (TA1026) for the full recommendations.
In practice, most people who respond well to Mounjaro stay on it for a year or more. The titration schedule alone (starting at 2.5mg and stepping up, typically every four weeks) means you may not reach your maintenance dose until around month five or six. The first pen's job is to let your system adjust. Meaningful weight loss accumulates over the months that follow, which is one reason clinical teams rarely assess whether treatment is working at the three-month mark.
Questions about how long can you be on Mounjaro often come from people wondering whether they will be cut off, and our guide to how long people typically stay on Mounjaro sets out what the evidence and clinical practice actually suggest. The honest answer is: not arbitrarily. Continuation is based on benefit, tolerability, and regular prescriber review.
This is the question most people are reluctant to ask, but it matters. The evidence from the tirzepatide trials is consistent with what researchers have seen across GLP-1 medicines broadly: when treatment stops, appetite tends to return, and weight regain is common. In the SURMOUNT trial programme, participants who discontinued after achieving significant weight loss did regain a meaningful proportion of that weight over the following year. The NHS medicines information on tirzepatide reflects this, noting that treatment is typically long-term.
This is not a failure of the medicine or the person. Obesity has a biological component, appetite-regulating hormones shift, and the body actively resists sustained weight loss. Tirzepatide works partly by mimicking the gut hormones GIP and GLP-1, which help regulate fullness and blood sugar. When you stop taking it, those effects stop too. If you are thinking about how long you have to stay on Mounjaro, your prescriber will weigh this up with you honestly when discussing how long to continue and what support looks like if treatment ends.
It is worth knowing that a prescriber can discuss stepping to a lower maintenance dose rather than stopping abruptly, depending on how things are going. That is a clinical conversation, and one worth having well before you run out of pens. If you are wondering about how long you have to take Mounjaro to see lasting results, that is exactly the kind of question to raise at your next review.
If you are factoring duration into the financial picture (which is completely reasonable) it is worth understanding that treatment is ongoing rather than a single outlay. Private Mounjaro pricing in the UK has shifted since Eli Lilly adjusted list prices in September 2025, with typical private costs now reported roughly between £149 and £375 per month depending on dose and provider. Our guide to Mounjaro pricing in the UK breaks this down in more detail, including what a single transparent price should include.
Duration matters here because many people start at a lower dose (and lower cost) and move up gradually. Some find a mid-range dose is enough and stay there; others need the higher doses to get the response they want. Either way, the monthly cost is not fixed across the whole treatment period, which makes a year-ahead budget harder to pin down exactly. What does not change at nume is the structure: one price covers consultation, prescription, delivery and aftercare, with no subscription locking you in and a prescriber reviewing every repeat order.
Every repeat order at a regulated service should come with a genuine clinical review, not a rubber stamp. A prescriber checks that the medicine is still doing what it should, that side effects are manageable, and that continuing makes sense at that dose. If you are losing weight steadily and tolerating treatment well, a conversation about the six-month checkpoint and longer-term planning (including what stopping might look like) is part of good care.
Our clinical team reviews every repeat before it is dispensed. For a broader look at what Mounjaro involves from the first dose onwards, the Mounjaro treatment overview is a useful starting point, and the nume FAQs cover many of the practical questions that come up once you are established on treatment. If you are still weighing up whether this is right for you, starting a free consultation is how that conversation begins with one of our GPhC-registered prescribers.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.